AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis. Its development programs and priorities may change as clinical studies progress.

Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also pursued collaborations and licensing arrangements with larger pharmaceutical companies. Historically, antibodies discovered using the company’s technology have contributed to programs such as dostarlimab, an immune checkpoint inhibitor subsequently developed and commercialized by another company. AnaptysBio is led by President and Chief Executive Officer Hamid Tabatabai.

Key Stats

• Today's Range: $45.81 to $47.19
• 50-Day Range: $45.65 to $59.69
• 52-Week Range: $20.18 to $72.36
• Volume: 495,168 shs
• Average Volume: 691,598 shs
• Market Capitalization: $1.37 billion
• P/E Ratio: 8.56
• Dividend Yield: N/A
• Price Target: $77.79
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 69% of companies evaluated by MarketBeat, and ranked 213th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

AnaptysBio has a consensus price target of $77.79, representing about 69.5% upside from its current price of $45.90.

Amount of Analyst Coverage

AnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($1.30) to $2.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is 8.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is 8.55, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.47.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 34.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.81% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 10.25, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 0.46%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.23

News Sentiment

AnaptysBio has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for AnaptysBio this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,350.00 in company stock.

Percentage Held by Insiders

31.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

AnaptysBio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/21/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 104
• Year Founded: 2005

Price Target and Rating

• Average Price Target for AnaptysBio: $77.79
• High Price Target: $100.00
• Low Price Target: $50.00
• Potential Upside/Downside: +69.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.37
• Trailing P/E Ratio: 8.56
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.23 million
• Net Margins: 82.37%
• Pretax Margin: -11.46%
• Return on Equity: 112.00%
• Return on Assets: 2.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.58
• Quick Ratio: 7.58

Sales & Book Value

• Annual Sales: $232.39 million
• Price / Sales: 5.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 34.29

Miscellaneous

• Outstanding Shares: 29,895,000
• Free Float: 20,478,000
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: 0.76